NCT07160686View on ClinicalTrials.gov

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,456

Participants

Timeline

Start Date

March 2, 2026

Primary Completion Date

September 30, 2029

Study Completion Date

March 30, 2030

Conditions
Thromboprophylaxis
Interventions
DRUG

Apixaban

apixaban 2.5mg twice a day for 6 months

OTHER

Placebo

Placebo twice a day for 6 months

Trial Locations (1)

B15 2TT

University of Birmingham, Birmingham

All Listed Sponsors
lead

University of Birmingham

OTHER